IP Library Granted Patent US 9,394,314
Granted Patent B2
US 9,394,314 · App. 14/134,100 · Granted Jul 19, 2016

8′-hydroxy-dihydroergotamine compounds and compositions

Inventors: Donald J. Kellerman (Mountain View, CA); Thomas Armer (Mountain View, CA); Jian Zhang (Mountain View, CA)
Assignee: MAP Pharmaceuticals, Inc.
C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,394,314
App. No.
14/134,100
Granted
Jul 19, 2016
Kind
B2
Abstract

8′-Hydroxy-Dihydroergotamine (8′-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of migraine disorders using the compounds, compositions, dosage forms and administration techniques disclosed herein.

Claims (11)

1. A method for treating, preventing or ameliorating one or more symptoms of a migraine disease, condition or disorder, said method comprising administering a therapeutically effective dose of an 8′-hydroxy-dihydroegotamine (8′-OH DHE) composition to a subject in need of migraine treatment.

2. The method of claim 1 , wherein said treatment comprises a reduction in a migraine symptom.

3. The method of claim 1 , wherein said treatment comprises provision of partial relief from at least one migraine symptom.

4. The method of claim 3 , wherein said treatment further comprises provision of sustained relief from one or more migraine symptom.

5. The method of claim 1 , wherein said treatment is further characterized by not inducing one or more drug-induced side-effect.

6. The method of claim 5 , wherein said treatment is further characterized by not inducing one or more drug-induced side-effect selected from nausea, emesis, chest tightness, and cardiovascular effects.

7. The method of claim 1 , wherein said 8′-OH DHE composition is administered at a rate sufficient to provide a maximum circulating plasma level (C max ) of 8′-OH DHE that is less than 500 pg/mL.

8. The method of claim 1 , wherein said 8′-OH DHE composition is administered at a rate sufficient to provide a maximum circulating plasma level (C max ) of 8′-OH DHE that is less than 2,500 pg/mL.

9. The method of claim 1 , wherein said 8′-OH DHE composition is administered at a rate sufficient to provide a maximum circulating plasma level (C max ) of 8′-OH DHE that is less than 5,000 pg/mL.

10. The method of claim 1 , wherein said 8′-OH DHE composition is administered in the form of a solution, suspension, tablet, dispersible tablet, pill, capsule, powder, sustained release composition, an elixir, a sterile solution or suspension suitable for parenteral administration, a topical dosage form, a transdermal dosage form, a nasal dosage form, or a pulmonary dosage form suitable for inhalation administration.

11. The method of claim 1 , wherein said 8′-OH DHE composition is administered using a nebulizer, a DPI device, a MDI device, or a pMDI device.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2014
From: KELLERMAN, DONALD J.; ARMER, THOMAS; ZHANG, JIAN
To: MAP PHARMACEUTICAL, INC.
Reel/Frame 032163/0696 →
Continuity (2)
Provisional Application 61745104 · Dec 21, 2012
Related Publication 20140179704A1 · Jun 26, 2014